Copyright © 2024 Research Nester. All Rights Reserved
Acromegaly Treatment Market size was over USD 2.16 billion in 2023 and is projected to reach USD 4.33 billion by 2036, growing at around 5.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of acromegaly treatment is assessed at USD 2.26 billion.
Acromegaly is a rare hormonal illness, caused due to excess production of growth hormones in the body. The pituitary gland in the brain, secretes growth hormone and in acromegaly, the pituitary gland secretes excessive amounts of growth hormone. It is one of the uncommon diseases, which is mostly diagnosed in middle-aged adults. Acromegaly is treated very effectively in most cases.
Growth Drivers
The increasing prevalence of hormonal diseases is one of the key factors projected to drive the market growth.
The rising awareness for acromegaly and an increase in the rates of screening globally is expected to fuel the overall market growth in the forecast period.
Progressions in surgery and developing alternatives, such as radiation therapy, medications, and others, are contributing towards the market growth. Developments in medical diagnoses, such as magnetic resonance imaging and the growth hormone suppression test, deliver the most selective means for the testing of acromegaly disorder. Medical advancements such as the development of antagonists (somatostatin analogs, dopamine agonists, and GH receptor antagonists), are the synthetic forms of natural hormones that restrict the creation of growth hormone. This is driving the market towards non-invasive treatments, mainly in cases where surgery is not a viable option.
The government through their supporting policies, schemes, and insurance, is surfaced as a major contributor towards the growth of the overall market.
Challenges
The high cost of surgery and lack of awareness for the diagnosis and management of the disorder in many developing nations may surface as key factors that might hamper the market growth.
Furthermore, complications accompanying the treatment, such as the risk of infection, ache, and reduced immunity, are likely to restrain the growth of the market.
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
5.5% |
|
Base Year Market Size (2023) |
USD 2.16 billion |
|
Forecast Year Market Size (2036) |
USD 4.33 billion |
|
Regional Scope |
|
The acromegaly treatment market is segmented by disease type, treatment, route of administration, distribution channel, and region. Among treatment segmentation, the medication segment is projected to drive the global market. Factors such as the efficiency of drugs, non-invasive treatments, lesser side effects than radiation therapies, and strong pipeline portfolio are likely to strengthen the growth of the overall market globally.
Our in-depth analysis of the global market includes the following segments:
|
By Disease Type |
|
|
By Treatment |
|
|
By Route Of Administration |
|
|
By Distribution Channel |
|
Geographically, the acromegaly treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America industry is predicted to dominate majority revenue share by 2036, attributed to factors such as availability of reimbursement, favorable government policies, an increase in the occurrence of pituitary tumors leading to acromegaly and gigantism, technological advancements, and rising awareness among people around the diagnosis of the disease in the region.
Europe is the second largest revenue contributor in the market, which is estimated to be led by Germany, France, and the U.K. The European regions have large healthcare infrastructure with many dominant market players operating in the market.
Asia-Pacific is estimated to grow at a rapid rate during the forecast period. Factors such as a growing economy, rising disposable income, increasing population, rising awareness, R&D initiatives, and increasing investment by the pharmaceutical companies is projected to present lucrative growth opportunities during the forecast period.
In the Middle East and Africa, the market is expected to be dominated by the prosperous Gulf economies of Saudi Arabia, Kuwait, UAE, and Qatar. However, the underprivileged income of African economies, together with poor social settings, might impede the market in Africa.
March 2020: Chiasma, a clinical-stage biopharmaceutical company, is developing an oral form of the drug octreotide for the maintenance treatment of acromegaly in adults which are not yet approved by the U.S. FDA. According to their research, octreotide capsules have the potential to work as an alternative to current injection therapy.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?